



December 15th, 2015

ViperGen enters into multi-target drug discovery agreement with Takeda

Copenhagen, Denmark, December 15th, 2015 - - ViperGen ApS announced today the signing of a multi-target drug discovery agreement with Takeda Pharmaceutical Company Limited. Under the terms of the agreement, ViperGen's small molecule discovery engine, a proprietary high fidelity DNA-encoded library technology platform, will be applied across therapeutic projects to identify novel hits/leads for selected targets from Takeda. Takeda obtains exclusive options to selected hits/leads and hit/lead series. The therapeutic areas of the targets were not disclosed. No information about the financial arrangement was provided.

"We are very proud to be selected by Takeda, a global industry leader in drug discovery and development," said Nils Hansen, Chief Executive Officer of ViperGen. "ViperGen has designed and implemented its discovery engine to deliver high quality hits and leads for very challenging but important protein targets such as Takeda is tackling to address unmet medical needs. We look forward to working with Takeda."

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda (TSE: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, <http://www.takeda.com>.

About ViperGen ApS

ViperGen is dedicated to small molecule drug discovery using DNA-encoded library platforms.

ViperGen leverages its innovative and proprietary drug discovery platforms in partnerships with leading pharmaceutical and biotech companies.

ViperGen's two 2nd generation technology platforms - The YoctoReactor[®] for synthesizing DNA-encoded chemical libraries and Binder Trap Enrichment[®] for screening of such libraries - are designed to deliver high fidelity drug discovery.

For further details about ViperGen and the YoctoReactor[®] / Binder Trap Enrichment[®] drug discovery technology platforms please visit www.viperGen.com or contact:

ViperGen ApS
Dr. Nils Hansen,
Chief Executive Officer
Phone: +45 2523 6680
nha@viperGen.com